GLP-1 (glucagon-like peptide-1) agonists are a class of medications that mainly help manage blood sugar (glucose) levels in people with Type 2 diabetes. Some GLP-1 agonists can also help treat obesity. GLP-1 agonist medicines include injections and oral medications.
The global Oral GLP-1 Agonist market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.
Key Features:
- Comprehensive analysis by region and market sector of projected Oral GLP-1 Agonist sales for 2024 through 2030.
- Detailed analysis in US$ millions of the world Oral GLP-1 Agonist industry.
- Evaluation of key market trends, drivers, and affecting factors shaping the global outlook for Oral GLP-1 Agonist.
Segmentation by Type:
- Semaglutide
- Non-peptide
Segmentation by Application:
- Diabetes
- Obesity
Market by Region:
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
Companies Coverage:
- Novo Nordisk
- Eli Lilly
Key Questions Addressed in this Report:
- What is the 10-year outlook for the global Oral GLP-1 Agonist market?
- What factors are driving Oral GLP-1 Agonist market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How do Oral GLP-1 Agonist market opportunities vary by end market size?
- How does Oral GLP-1 Agonist break out by Type, by Application?
Frequently Asked Questions
What is the USP of the report? expand_more
Oral GLP-1 Agonist report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
What are the key content of the report? expand_more
Oral GLP-1 Agonist report is categorised based on following features:
- Global Market Players
- Geopolitical regions
- Consumer Insights
- Technological advancement
- Historic and Future Analysis of the Market
What are the value propositions and opportunities offered in this market research report? expand_more
Oral GLP-1 Agonist report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.